In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thera Neuropharma, Inc.

http://www.theraneuro.com/index.html

Latest From Thera Neuropharma, Inc.

Deals Shaping The Medical Industry, June 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.

BioPharmaceutical Medical Device

Deal Statistics Quarterly, February-May 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case February 2001-May 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.

BioPharmaceutical Medical Device

Inverness Strengthens Its Hand; Cygnus Plays a Card

Inverness Medical Technology's purchase of struggling diabetes testing start-up LXN fits well with the larger company'stwo-pronged strategy of cementing its relationship with J&J's LifeScan Inc. business unit and diversifying into emerging areas of diabetes testing. Inverness also announced that the partners have amended their distribution and marketing agreement to give LifeScan bigger discounts on meters in return for bigger purchase orders.

Medical Device Strategy

Cloning Lifescan

Looking for high acquisition valuations like those paid for Lifescan by J&J and for Medisense by Abbott, a host of new diabetes start-ups are trying to develop alternatives to finger-stick home glucose testing. Most companies are developing less-invasive or non-invasive technologies to reduce or entirely eliminate the pain of testing. LXN, on the other hand, is aiming to improve glucose control through an at-home version of the state-of-the-art glycated protein test.

Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Other Names / Subsidiaries
    • Thera Neuropharma
UsernamePublicRestriction

Register